Illumina brings whole-genome sequencing to German hospital

By LabPulse.com staff writers

April 27, 2022 -- Illumina has signed an agreement with Hannover Medical School in Germany to assess the use of rapid whole-genome sequencing (rWGS) in critically ill children suspected of having a genetic or rare disease.

Under the project, the diagnostic efficacy of rWGS will be evaluated in the institution's neonatal and pediatric intensive care units, according to the company. At least 100 critically ill children with suspected genetic disorders will be tested, as well as their parents when possible.

Illumina said that the study results will be used to challenge the existing inclusion and exclusion criteria for rWGS in intensive care settings, as well as to help establish appropriate evidence for earlier use of the test in the German healthcare system. Furthermore, researchers will also review changes in patient care and management to determine the clinical utility of rWGS, according to the company.

Finally, the test's financial impact will be analyzed by comparing the costs of rWGS with the existing diagnostic pathway for a critically ill child with a suspected genetic disorder, according to Illumina.

Illumina hits Guardant with lawsuit over trade secrets
Illumina has hit Guardant Health with a lawsuit alleging Guardant and its founders Helmy Eltoukhy and AmirAli Talasaz misappropriated Illumina's trade...
Illumina releases in vitro cancer profiling test
Illumina has launched TruSight Oncology Comprehensive, a test that examines tumor genes and biomarkers to define the specific molecular profile of a patient's...
Beckman Coulter inks deal with Illumina for NGS library prep
Beckman Coulter Life Sciences has signed an agreement with Illumina to access that company's next-generation sequencing (NGS) technology to incorporate...
Illumina to collaborate with Japan's National Cancer Center
Illumina and Japan's National Cancer Center have announced a collaboration that will use Illumina's DNA sequencing assay TruSight Oncology 500 ctDNA to...
Agendia, Illumina partner on genomic testing for breast cancer
Precision oncology firm Agendia has announced a multiyear partnership with Illumina to co-develop IVD tests for oncology testing. The companies aim to...

Copyright © 2022 LabPulse.com

Last Updated mp 4/27/2022 6:42:23 AM